rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    KROS
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Keros Therapeutics Announces Additional $5 Million Share Repurchase Authorization

      LEXINGTON, Mass., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that its Board of Directors has approved a new $5 million share repurchase program of the Company’s

      Nov 16Yahoo FinanceKROS
      Keros earnings beat by $1.64, revenue topped estimates
      Nov 6Investing.comKROS
      Keros Therapeutics, Inc. (KROS) Q3 Earnings and Revenues Surpass Estimates
      Nov 5Yahoo FinanceKROS
      Keros Therapeutics Eyes 2027 DMD Data as Rinvatercept Takes Center Stage
      Oct 22Yahoo FinanceKROS
      Keros Therapeutics at Chardan conference: reset turns to pipeline data
      Oct 20Investing.comKROS
      Keros Therapeutics Expects $20 Million Milestone Payment From Takeda

      Keros Therapeutics (KROS) said Tuesday it expects to receive a $20 million development milestone pay

      Sep 29Yahoo FinanceKROSTAK
      Keros Therapeutics to receive $20M milestone from Takeda
      Sep 29Investing.comKROS
      Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda
      Sep 29Yahoo FinanceKROSTAK
      Keros doses first patient in DMD trial of rinvatercept
      Sep 28Investing.comKROS
      Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD

      Initial data expected in the first half of 2027LEXINGTON, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that the first patient was dosed in the Phase 2 clinical trial of ri

      Sep 28Yahoo FinanceKROS
      Keros Therapeutics Announces $5 Million Share Repurchase Authorization

      LEXINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that its Board of Directors has approved a $5 million share repurchase program of the Company’s co

      Sep 8Yahoo FinanceKROS
      Keros Therapeutics Approves $5 Million Share Buyback

      Keros Therapeutics' (KROS) board approved a $5 million share repurchase program following receipt of

      Sep 8Yahoo FinanceKROS
      Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report?

      Keros Therapeutics (KROS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      Sep 2Yahoo FinanceKROS
      Keros Therapeutics director Bienaime buys $10,270 in shares
      Sep 2Investing.comKROS
      Keros Therapeutics director Bienaime buys $10,270 of KROS stock
      Aug 28Investing.comKROS
      KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak

      Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

      Aug 24The Globe and MailKROS

      This is the newest page. Registered accounts read further back.